908761918	908761918	CD	B-NP	O
|	|	NN	I-NP	O
AVMC	AVMC	NN	I-NP	O
|	|	NN	I-NP	O
45427009	45427009	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
4087953	4087953	CD	B-NP	O
|	|	CC	I-NP	O
5/26/2007	5/26/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Gemella	Gemella	NN	I-NP	O
morbillorum	morbillorum	NN	I-NP	O
bacteremia	bacteremia	NN	I-NP	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
endocarditis	endocarditis	NN	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/21/2007	2/21/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
9/29/2007	9/29/2007	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NN	I-NP	O
******	******	SYM	B-NP	O
DADAMO	DADAMO	NN	I-NP	O
,	,	,	O	O
WILTON	WILTON	NNP	B-NP	O
T	T	NNP	I-NP	O
981-00-02-7	981-00-02-7	CD	I-NP	O
Parkant	Parkant	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
1/15/07	1/15/07	CD	B-NP	O
AT	AT	NN	I-NP	O
03	03	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
Attending	Attend	VBG	B-VP	O
evaluation	evaluation	NN	B-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
ROCKWELL	ROCKWELL	NNP	B-NP	O
,	,	,	O	O
ANTIONE	ANTIONE	NNP	B-NP	O
J.	J.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Rehabilitation	Rehabilitation	NNP	B-NP	O
MEDICATIONS	MEDICATIONS	NNP	I-NP	O
ON	ON	NNP	I-NP	O
ADMISSION	ADMISSION	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

ACETAMINOPHEN	ACETAMINOPHEN	NN	B-NP	O
650	650	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
Q6H	Q6H	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
325	325	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

ALBUTEROL	ALBUTEROL	NN	B-NP	O
NEBULIZER	NEBULIZER	NN	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NN	I-NP	O
NEB	NEB	NN	I-NP	O
Q4H	Q4H	NN	I-NP	O
4	4	CD	I-NP	O
.	.	.	O	O

DOCUSATE	DOCUSATE	JJ	B-NP	O
SODIUM	SODIUM	NN	I-NP	O
100	100	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	B-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

FLUTICASONE	FLUTICASONE	NNP	B-NP	O
NASAL	NASAL	NNP	I-NP	O
SPRAY	SPRAY	NNP	I-NP	O
2	2	CD	I-NP	O
SPRAY	SPRAY	NN	I-NP	O
NA	NA	NN	I-NP	O
QD	QD	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

HEPARIN	HEPARIN	NN	B-NP	O
5000	5000	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NN	I-NP	O
Q8H	Q8H	NN	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

INSULIN	INSULIN	NNP	B-NP	B-protein
GLARGINE	GLARGINE	NNP	I-NP	O
32	32	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
QHS	QHS	NNP	I-NP	B-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

KCL	KCL	NN	B-NP	B-protein
SLOW	SLOW	NN	I-NP	I-protein
RELEASE	RELEASE	NN	I-NP	I-protein
TAB	TAB	NN	I-NP	I-protein
40	40	CD	I-NP	I-protein
MEQ	MEQ	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
9	9	CD	I-NP	I-protein
.	.	.	O	O

NIFEREX	NIFEREX	NN	B-NP	B-protein
150	150	CD	I-NP	I-protein
150	150	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
BID	BID	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

PANTOPRAZOLE	PANTOPRAZOLE	NN	B-NP	O
40	40	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
Q12	Q12	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

SENNOSIDES	SENNOSIDES	NNS	B-NP	O
2	2	CD	I-NP	O
TAB	TAB	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

SIMVASTATIN	SIMVASTATIN	NN	B-NP	O
40	40	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

ALBUTEROL	ALBUTEROL	NN	B-NP	O
NEBULIZER	NEBULIZER	NN	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NN	I-NP	O
NEB	NEB	NN	I-NP	O
Q12H	Q12H	NN	I-NP	O
14	14	CD	I-NP	O
.	.	.	O	O

SARNA	SARNA	NNP	B-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
TOP	TOP	NNP	I-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
15	15	CD	I-NP	O
.	.	.	O	O

FUROSEMIDE	FUROSEMIDE	NN	B-NP	B-protein
80	80	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QAM	QAM	NNP	I-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

FLUTICASONE	FLUTICASONE	NN	B-NP	B-protein
PROPIONATE	PROPIONATE	NN	I-NP	I-protein
110	110	CD	I-NP	I-protein
MCG	MCG	NN	I-NP	I-protein
ORAL	ORAL	NN	I-NP	I-protein
INHALER	INHALER	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
PUFFS	PUFFS	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
17	17	CD	I-NP	I-protein
.	.	.	O	O

INSULIN	INSULIN	NNP	B-NP	B-protein
LISPRO	LISPRO	NNP	I-NP	O
SLIDING	SLIDING	NNP	I-NP	O
SCALE	SCALE	NNP	I-NP	O
SC	SC	NNP	I-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

LOSARTAN	LOSARTAN	NN	B-NP	O
50	50	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

THERAPEUTIC	THERAPEUTIC	NN	B-NP	O
MULTIVITAMINS	MULTIVITAMINS	NN	I-NP	O
1	1	CD	I-NP	O
TAB	TAB	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
20	20	CD	I-NP	O
.	.	.	O	O

MAALOX	MAALOX	NNP	B-NP	O
EXTRA	EXTRA	NNP	I-NP	O
STRENGTH	STRENGTH	NNP	I-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
PO	PO	NNP	I-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
21	21	CD	I-NP	O
.	.	.	O	O

POLYETHYLENE	POLYETHYLENE	NN	B-NP	B-protein
GLYCOL	GLYCOL	NN	I-NP	I-protein
17	17	CD	I-NP	I-protein
GM	GM	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	O
22	22	CD	I-NP	O
.	.	.	O	O

DIPHENHYDRAMINE	DIPHENHYDRAMINE	NN	B-NP	O
25	25	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
23	23	CD	I-NP	O
.	.	.	O	O

BISACODYL	BISACODYL	NNP	B-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
PO	PO	NNP	I-NP	O
UNKNOWN	UNKNOWN	NNP	I-NP	O
MEDICATIONS	MEDICATIONS	NNP	I-NP	O
ON	ON	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
:	:	:	O	O
MICONAZOLE	MICONAZOLE	NN	B-NP	O
NITRATE	NITRATE	NN	I-NP	O
2	2	CD	B-NP	O
%	%	NN	I-NP	O
POWDER	POWDER	NN	I-NP	O
TOPICAL	TOPICAL	NN	I-NP	O
TP	TP	NN	I-NP	O
BID	BID	NN	I-NP	O
Instructions	Instruction	NNS	I-NP	O
:	:	:	O	O
apply	apply	VB	B-VP	O
to	to	TO	B-PP	O
pannus	pannus	NN	B-NP	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	I-NP	O
ACID	ACID	NN	I-NP	O
325	325	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
ALBUTEROL	ALBUTEROL	NN	I-NP	O
NEBULIZER	NEBULIZER	NN	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NN	I-NP	O
NEB	NEB	NN	I-NP	O
Q6H	Q6H	NN	I-NP	O
PRN	PRN	NN	I-NP	O
Wheezing	Wheeze	VBG	B-VP	O
ALBUTEROL	ALBUTEROL	NN	B-NP	O
NEBULIZER	NEBULIZER	NN	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NN	I-NP	O
NEB	NEB	NN	I-NP	O
Q12H	Q12H	NN	I-NP	O
NEOMYCIN/POLY	NEOMYCIN/POLY	NN	I-NP	O
B/BACITRACIN	B/BACITRACIN	NN	I-NP	O
OINTMENT	OINTMENT	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
BACITRAC	BACITRAC	NN	I-NP	O
...	...	:	O	O
-RRB-	-RRB-	SYM	B-NP	O
TOPICAL	TOPICAL	NN	I-NP	O
TP	TP	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
Instructions	Instruction	NNS	I-NP	O
:	:	:	O	O
apply	apply	VB	B-VP	O
to	to	TO	B-PP	O
right	right	JJ	B-NP	O
hand	hand	NN	I-NP	O
lesion	lesion	NN	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
3/10/07	3/10/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
FUROSEMIDE	FUROSEMIDE	NNP	B-NP	O
&	&	CC	I-NP	O
NEOMYCIN	NEOMYCIN	NNP	I-NP	O
SULFATE	SULFATE	NNP	I-NP	O
,	,	,	O	O
TOPICAL	TOPICAL	NNP	B-NP	O
OR	OR	NNP	I-NP	O
OPHTH	OPHTH	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
DULCOLAX	DULCOLAX	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
BISACODYL	BISACODYL	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
5	5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Constipation	Constipation	NNP	I-NP	O
CEFTRIAXONE	CEFTRIAXONE	NNP	I-NP	O
2	2	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
MG	MG	NNP	I-NP	O
IV	IV	CD	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
5/2	5/2	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
to	to	TO	B-VP	O
end	end	VB	I-VP	O
11/7/07	11/7/07	CD	B-NP	O
COLACE	COLACE	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
DOCUSATE	DOCUSATE	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
100	100	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
FLUTICASONE	FLUTICASONE	NNP	I-NP	O
NASAL	NASAL	NNP	I-NP	O
SPRAY	SPRAY	NNP	I-NP	O
1	1	CD	I-NP	O
SPRAY	SPRAY	NN	I-NP	O
NA	NA	NN	I-NP	O
BID	BID	NN	I-NP	O
FLOVENT	FLOVENT	NN	I-NP	O
HFA	HFA	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
FLUTICASONE	FLUTICASONE	NN	I-NP	O
PROPIONATE	PROPIONATE	NN	I-NP	O
INH	INH	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
110	110	CD	I-NP	O
MCG	MCG	NNP	I-NP	O
INH	INH	NNP	I-NP	O
BID	BID	NNP	I-NP	O
LASIX	LASIX	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
80	80	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
IN	IN	NNP	I-NP	O
AM	AM	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
7/26	7/26	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/25/07	7/25/07	CD	B-NP	O
by	by	IN	B-PP	O
MCKEANE	MCKEANE	NNP	B-NP	O
,	,	,	O	O
GROVER	GROVER	NNP	B-NP	O
S.	S.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LASIX	LASIX	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
515768930	515768930	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
Sulfa	Sulfa	NNP	B-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
no	no	DT	B-NP	O
reaction	reaction	NN	I-NP	O
Previous	Previous	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
Override	Override	NNP	I-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
7/25/07	7/25/07	CD	B-NP	O
by	by	IN	B-PP	O
STINES	STINES	NNS	B-NP	O
,	,	,	O	O
TOBY	TOBY	NNP	B-NP	O
F.	F.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
GENTAMICIN	GENTAMICIN	NNP	B-NP	O
SULFATE	SULFATE	NNP	I-NP	O
&	&	CC	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
GENTAMICIN	GENTAMICIN	NN	I-NP	O
SULFATE	SULFATE	NN	I-NP	O
80	80	CD	B-NP	O
MG	MG	NN	I-NP	O
IV	IV	CD	B-NP	O
DAILY	DAILY	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
5/2	5/2	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
at	at	IN	B-ADVP	O
least	least	JJS	I-ADVP	O
for	for	IN	B-PP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
until	until	IN	B-PP	O
11/27/07	11/27/07	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
7/25/07	7/25/07	CD	B-NP	O
by	by	IN	B-PP	O
WYSOCKI	WYSOCKI	NNP	B-NP	O
,	,	,	O	O
ALAN	ALAN	NNP	B-NP	O
L.	L.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LASIX	LASIX	NN	B-NP	B-protein
PO	PO	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ref	ref	NN	I-NP	I-protein
#	#	#	B-NP	I-protein
515768930	515768930	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
GENTAMICIN	GENTAMICIN	NNP	B-NP	O
SULFATE	SULFATE	NNP	I-NP	O
&	&	CC	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/25/07	7/25/07	CD	B-NP	O
by	by	IN	B-PP	O
NISSILA	NISSILA	NNP	B-NP	O
,	,	,	O	O
CHRIS	CHRIS	NNP	B-NP	O
J.	J.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LASIX	LASIX	NNP	B-NP	O
INJ	INJ	NNP	I-NP	O
IV	IV	CD	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	I-NP	O
782911242	782911242	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
GENTAMICIN	GENTAMICIN	NNP	B-NP	O
SULFATE	SULFATE	NNP	I-NP	O
&	&	CC	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
,	,	,	O	O
INJ	INJ	NNP	B-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
HEPARIN	HEPARIN	NN	I-NP	O
5	5	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
UNITS	UNITS	NNS	I-NP	O
SC	SC	NN	I-NP	O
Q8H	Q8H	NN	I-NP	O
Instructions	Instruction	NNS	I-NP	O
:	:	:	O	O
please	please	VB	B-VP	O
give	give	VB	B-NP	O
as	as	IN	B-SBAR	O
instructed	instruct	VBN	B-VP	O
until	until	IN	B-PP	O
pt	pt	NN	B-NP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
bed	bed	NN	B-NP	O
and	and	CC	O	O
ambulatory	ambulatory	JJ	B-ADJP	O
.	.	.	O	O

LANTUS	LANTUS	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
GLARGINE	GLARGINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
36	36	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
BEDTIME	BEDTIME	NNP	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
please	please	VB	B-INTJ	O
give	give	VB	B-NP	O
1/2	1/2	CD	B-NP	O
dose	dose	NN	I-NP	O
if	if	IN	B-SBAR	O
NPO	NPO	NNP	B-NP	B-protein
LISPRO	LISPRO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
LISPRO	LISPRO	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Sliding	Sliding	NNP	I-NP	O
Scale	Scale	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
subcutaneous	subcutaneous	JJ	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
SC	SC	NNP	I-NP	O
AC	AC	NNP	I-NP	O
Low	Low	NNP	I-NP	O
Scale	Scale	NNP	I-NP	O
Call	Call	NNP	I-NP	O
HO	HO	NN	I-NP	O
if	if	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
60	60	CD	I-NP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
125	125	CD	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
DO	DO	NNP	B-NP	O
NOT	NOT	NNP	I-NP	O
Administer	Administer	NNP	I-NP	O
supplemental	supplemental	JJ	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
insulin	insulin	NN	I-NP	I-protein
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
125-150	125-150	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
151-200	151-200	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
1	1	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
201-250	201-250	CD	B-NP	O
,	,	,	O	O
then	then	RB	O	O
give	give	VB	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
251-300	251-300	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
301-350	301-350	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
351-400	351-400	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
5	5	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
Call	Call	VBP	B-VP	O
HO	HO	NN	B-NP	B-protein
if	if	IN	B-SBAR	I-protein
BS	BS	NNP	B-NP	I-protein
is	be	VBZ	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
350	350	CD	B-NP	O
If	If	IN	B-SBAR	O
ordered	order	VBN	B-NP	O
QAC	QAC	NN	I-NP	O
administer	administer	NN	I-NP	O
at	at	IN	B-PP	O
same	same	JJ	B-NP	O
time	time	NN	I-NP	O
as	as	IN	B-PP	O
,	,	,	O	O
and	and	CC	O	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
,	,	,	O	O
standing	stand	VBG	B-VP	O
insulin	insulin	NN	B-NP	O
aspart	aspart	NN	I-NP	O
order	order	NN	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
ordered	order	VBN	B-NP	O
HS	HS	NN	I-NP	O
administer	administer	NN	I-NP	O
alone	alone	RB	B-ADVP	O
K-DUR	K-DUR	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
KCL	KCL	NNP	I-NP	O
SLOW	SLOW	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
TAB	TAB	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
40	40	CD	I-NP	O
MEQ	MEQ	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
As	As	IN	B-PP	O
per	per	IN	B-PP	O
SMC	SMC	NNP	B-NP	B-cell_type
Potassium	Potassium	NNP	I-NP	O
Chloride	Chloride	NNP	I-NP	O
Policy	Policy	NNP	I-NP	O
:	:	:	O	O
each	each	DT	B-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
with	with	IN	B-PP	O
4	4	CD	B-NP	O
oz	oz	NN	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	NN	B-NP	B-protein
NIFEREX	NIFEREX	NN	I-NP	I-protein
150	150	CD	I-NP	I-protein
150	150	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
PANTOPRAZOLE	PANTOPRAZOLE	NNP	I-NP	I-protein
40	40	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
Q12H	Q12H	NN	I-NP	I-protein
MIRALAX	MIRALAX	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
POLYETHYLENE	POLYETHYLENE	NN	I-NP	I-protein
GLYCOL	GLYCOL	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
17	17	CD	I-NP	I-protein
GM	GM	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Constipation	Constipation	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
4	4	CD	B-NP	O
SARNA	SARNA	NN	I-NP	O
TOPICAL	TOPICAL	NN	I-NP	O
TP	TP	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
PRN	PRN	NN	I-NP	O
Itching	Itch	VBG	B-VP	O
SENNA	SENNA	NN	B-NP	O
TABLETS	TABLETS	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
SENNOSIDES	SENNOSIDES	NN	I-NP	B-DNA
-RRB-	-RRB-	HYPH	B-NP	I-DNA
2	2	CD	I-NP	I-DNA
TAB	TAB	NN	I-NP	I-DNA
PO	PO	NN	I-NP	I-DNA
BID	BID	NN	I-NP	I-DNA
SIMVASTATIN	SIMVASTATIN	NN	I-NP	I-DNA
40	40	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BEDTIME	BEDTIME	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Override	Override	NNP	B-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
11/18/07	11/18/07	CD	B-NP	O
by	by	IN	B-PP	O
BANG	BANG	NNP	B-NP	O
,	,	,	O	O
ELDON	ELDON	NNP	B-NP	O
A.	A.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
MULTIVITAMIN	MULTIVITAMIN	NN	B-NP	O
THERAPEUTIC	THERAPEUTIC	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
138418200	138418200	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NNP	B-NP	O
&	&	CC	I-NP	O
NIACIN	NIACIN	NNP	I-NP	O
,	,	,	O	O
VIT	VIT	NNP	B-NP	O
.	.	.	O	O

B-3	B-3	NN	B-NP	B-protein
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
md	md	NN	B-NP	O
aware	aware	JJ	I-NP	O
MULTIVITAMIN	MULTIVITAMIN	NN	I-NP	O
THERAPEUTIC	THERAPEUTIC	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
THERAPEUTIC	THERAPEUTIC	NN	I-NP	O
MULTIVI	MULTIVI	NN	I-NP	O
...	...	:	O	O
-RRB-	-RRB-	SYM	B-NP	O
1	1	CD	I-NP	O
TAB	TAB	NN	I-NP	B-protein
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/18/07	11/18/07	CD	B-NP	O
by	by	IN	B-PP	O
KULESA	KULESA	NNP	B-NP	O
,	,	,	O	O
FAUSTO	FAUSTO	NNP	B-NP	O
J.	J.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NNP	B-NP	O
&	&	CC	I-NP	O
NIACIN	NIACIN	NNP	I-NP	O
,	,	,	O	O
VIT	VIT	NNP	B-NP	O
.	.	.	O	O

B-3	B-3	NN	B-NP	B-protein
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
md	md	NN	B-NP	O
aware	aware	JJ	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
Fluid	Fluid	NN	B-NP	O
restriction	restriction	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	O	O
ADA	ADA	NN	B-NP	O
1800	1800	CD	I-NP	O
cals/dy	cals/dy	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
2	2	CD	B-NP	O
gram	gram	NN	I-NP	O
Sodium	Sodium	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Paris	Paris	NNP	I-NP	O
Tribue	Tribue	NNP	I-NP	O
10/29/07	10/29/07	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
45	45	CD	B-NP	O
PM	PM	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Chadwick	Chadwick	NNP	I-NP	O
Delvin	Delvin	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Infectious	Infectious	NNP	I-NP	O
Disease	Disease	NNP	I-NP	O
Clinic	Clinic	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
7/19/07	7/19/07	CD	I-NP	O
8am	8am	CD	I-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Jerrold	Jerrold	NNP	I-NP	O
Elhadi	Elhadi	NNP	I-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
call	call	VBP	B-VP	O
for	for	IN	B-PP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
rehab	rehab	NN	B-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
Sulfa	Sulfa	NN	B-NP	O
,	,	,	O	O
TETRACYCLINE	TETRACYCLINE	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
bacteremia	bacteremia	NN	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Gemella	Gemella	NNP	I-NP	O
morbillorum	morbillorum	NN	I-NP	O
bacteremia	bacteremia	NN	I-NP	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
endocarditis	endocarditis	NN	I-NP	O
OTHER	OTHER	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
chf	chf	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
dm	dm	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
cad	cad	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
af	af	IN	B-PP	O
-LRB-	-LRB-	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
htn	htn	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hypertension	hypertension	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
hypercholesterolemia	hypercholesterolemia	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
elevated	elevated	JJ	I-NP	O
cholesterol	cholesterol	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
TEE	TEE	NNP	I-NP	O
6/18/07	6/18/07	CD	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
CC	CC	NN	B-NP	O
:	:	:	O	O
fever	fever	NN	B-NP	O
,	,	,	O	O
+	+	CC	O	O
blood	blood	NN	B-NP	O
cx	cx	NN	I-NP	O
,	,	,	O	O
r/o	r/o	NN	B-NP	O
endocarditis	endocarditis	NN	I-NP	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
HPI	HPI	NN	B-NP	O
:	:	:	O	O
82	82	CD	B-NP	O
year	year	NN	I-NP	O
old	old	JJ	I-NP	O
man	man	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
PMH	PMH	NN	I-NP	B-protein
s/f	s/f	NN	I-NP	I-protein
AVR	AVR	NN	I-NP	I-protein
for	for	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
August	August	NNP	I-NP	O
,	,	,	O	O
2007	2007	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	B-protein
s/p	s/p	NN	I-NP	I-protein
CABG	CABG	NN	I-NP	I-protein
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ef	ef	NN	I-NP	I-protein
60	60	CD	B-NP	I-protein
%	%	NN	I-NP	I-protein
6/12	6/12	CD	B-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-VP	O
SVR	SVR	NN	B-NP	B-protein
,	,	,	O	O
IDDM	IDDM	NN	B-NP	O
,	,	,	O	O
Fe	Fe	NN	B-NP	O
def	def	NN	I-NP	O
anemia	anemia	NN	I-NP	O
and	and	CC	O	O
hemorrahgic	hemorrahgic	JJ	B-NP	B-protein
stroke	stroke	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
~	~	NN	I-NP	I-protein
6	6	CD	B-NP	I-protein
months	month	NNS	I-NP	I-protein
ago	ago	IN	B-PP	I-protein
-RRB-	-RRB-	NN	B-NP	I-protein
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
from	from	IN	B-PP	O
Tanands	Tanands	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
fever	fever	NN	B-NP	O
-LRB-	-LRB-	HYPH	O	O
2	2	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
presentation	presentation	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
positive	positive	JJ	B-NP	O
UA	UA	NN	I-NP	O
and	and	CC	O	O
blood	blood	NN	B-NP	O
culture	culture	NN	I-NP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
gram	gram	NN	B-NP	O
positive	positive	JJ	I-NP	O
cocci	coccus	NNS	I-NP	O
in	in	IN	B-PP	O
clusters	cluster	NNS	B-NP	O
.	.	.	O	O

Concern	Concern	NN	B-NP	O
that	that	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
endocarditis	endocarditis	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
other	other	JJ	I-NP	O
systemic	systemic	JJ	I-NP	O
signs	sign	NNS	I-NP	O
or	or	CC	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	:	O	O
PMH	PMH	NN	B-NP	O
:	:	:	O	O
s/p	s/p	NN	B-NP	B-protein
AVR	AVR	NN	I-NP	I-protein
-LRB-	-LRB-	HYPH	O	O
11/29	11/29	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
htn	htn	NN	B-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
cad	cad	NN	B-NP	B-protein
w	w	NN	I-NP	I-protein
/	/	SYM	B-NP	I-protein
cabg	cabg	NN	I-NP	I-protein
x3	x3	NN	I-NP	I-protein
,	,	,	O	O
a	a	DT	B-NP	O
fib	fib	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-VP	O
svr	svr	NN	B-NP	O
,	,	,	O	O
iddm	iddm	NN	B-NP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
hemorrhagic	hemorrhagic	JJ	I-NP	O
stroke	stroke	NN	I-NP	O
9/21	9/21	CD	I-NP	O
,	,	,	O	O
bph	bph	NN	B-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
suprapubic	suprapubic	JJ	I-NP	O
cath	cath	NN	I-NP	O
placement	placement	NN	I-NP	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
HOME	HOME	NN	B-NP	O
MEDS	MEDS	NN	I-NP	O
:	:	:	O	O
albuterol	albuterol	NN	B-NP	O
,	,	,	O	O
asa	asa	NN	B-NP	O
,	,	,	O	O
sarna	sarna	NN	B-NP	O
,	,	,	O	O
colace	colace	NN	B-NP	O
,	,	,	O	O
fluticasone	fluticasone	NN	B-NP	O
,	,	,	O	O
lasix	lasix	CD	B-NP	O
80	80	CD	I-NP	O
qam	qam	NN	I-NP	O
,	,	,	O	O
lispro	lispro	NN	B-NP	O
SS	SS	NNP	I-NP	O
,	,	,	O	O
lantus	lantus	NN	B-NP	O
32u	32u	CD	I-NP	O
qhs	qh	NNS	I-NP	O
,	,	,	O	O
simvastatin	simvastatin	NN	B-NP	O
,	,	,	O	O
tylenol	tylenol	NN	B-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
,	,	,	O	O
losartan	losartan	NN	B-NP	O
,	,	,	O	O
mvi	mvi	NN	B-NP	O
iron	iron	NN	I-NP	O
,	,	,	O	O
kcl	kcl	NN	B-NP	O
,	,	,	O	O
protonix	protonix	NN	B-NP	O
,	,	,	O	O
maalox	maalox	NN	B-NP	O
,	,	,	O	O
dulcolax	dulcolax	NN	B-NP	O
,	,	,	O	O
benadryl	benadryl	NN	B-NP	O
,	,	,	O	O
miralax	miralax	NN	B-NP	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	:	O	O
ALL	ALL	NN	B-NP	O
:	:	:	O	O
sulfa	sulfa	NN	B-NP	O
--	--	:	O	O
swelling	swelling	NN	B-NP	O
;	;	:	O	O
tetracycline	tetracycline	NN	B-NP	O
--	--	:	O	O
swelling	swelling	NN	B-NP	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	HYPH	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
EXAM	EXAM	NN	I-NP	O
:	:	:	O	O
VS	VS	NN	B-NP	O
:	:	:	O	O
98.5	98.5	CD	B-NP	O
F	F	NN	I-NP	O
,	,	,	O	O
hr	hr	NN	B-NP	O
49	49	CD	I-NP	O
,	,	,	O	O
bp160/56	bp160/56	NN	B-NP	O
,	,	,	O	O
sat	sit	VBD	B-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
ra	ra	NN	I-NP	O
gen-nad	gen-nad	NN	I-NP	O
;	;	:	O	O
heent-o/p	heent-o/p	NN	B-NP	O
clear	clear	JJ	B-ADJP	O
,	,	,	O	O
no	no	DT	B-NP	O
icterius	icterius	NN	I-NP	O
;	;	:	O	O
neck-fupple	neck-fupple	NN	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
lan	lan	NN	I-NP	O
,	,	,	O	O
fvp	fvp	NN	B-NP	O
to	to	TO	B-VP	O
ear	ear	VB	I-VP	O
;	;	:	O	O
cv-brady	cv-brady	JJ	B-NP	O
irreg	irreg	NN	I-NP	O
irreg	irreg	NN	I-NP	O
,	,	,	O	O
4/8	4/8	CD	B-NP	O
sem	sem	NN	I-NP	O
at	at	IN	B-PP	O
lusb	lusb	NN	B-NP	O
;	;	:	O	O
pulm-crackles	pulm-crackle	NNS	B-NP	O
at	at	IN	B-PP	O
bases	base	NNS	B-NP	O
b/l	b/l	NN	I-NP	O
;	;	:	O	O
abd-benign	abd-benign	JJ	B-ADJP	O
;	;	:	O	O
no	no	DT	B-NP	O
stigmata	stigmata	NN	I-NP	O
of	of	IN	B-PP	O
endocarditis	endocarditis	NN	B-NP	O
;	;	:	O	O
extr-1	extr-1	NN	B-NP	O
+	+	SYM	I-NP	O
pitting	pitting	NN	I-NP	O
edema	edema	NN	I-NP	O
to	to	TO	B-PP	O
ankles	ankle	NNS	B-NP	O
b/l	b/l	NN	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
pulses	pulse	NNS	I-NP	O
b/l	b/l	NN	I-NP	O
,	,	,	O	O
wwp	wwp	NN	B-NP	O
--	--	:	O	O
--	--	:	O	O
-	-	HYPH	B-NP	O
ADMIT	ADMIT	NN	I-NP	B-protein
LABS	LABS	NN	I-NP	I-protein
:	:	:	O	O
CR	CR	NN	B-NP	B-protein
1.9	1.9	CD	I-NP	I-protein
-LRB-	-LRB-	:	O	O
baseline	baseline	NN	B-NP	O
1.3	1.3	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
hct	hct	NN	B-NP	B-protein
31	31	CD	I-NP	I-protein
-LRB-	-LRB-	:	O	I-protein
baseline	baseline	NN	B-NP	I-protein
29	29	CD	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
,	,	,	O	O
wbc	wbc	NN	B-NP	B-protein
8	8	CD	I-NP	I-protein
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	:	O	O
DATA	DATA	NN	B-NP	O
:	:	:	O	O
CXR	CXR	NN	B-NP	B-protein
:	:	:	O	O
improved	improve	VBN	B-NP	O
L	L	NN	I-NP	O
pleural	pleural	JJ	I-NP	O
effusion	effusion	NN	I-NP	O
EKG	EKG	NN	I-NP	O
:	:	:	O	O
a	a	DT	B-NP	O
fib	fib	NN	I-NP	O
@	@	NN	I-NP	O
44	44	CD	I-NP	O
,	,	,	O	O
lad	lad	NN	B-NP	O
,	,	,	O	O
rbbb	rbbb	NN	B-NP	O
,	,	,	O	O
old	old	JJ	B-NP	O
q	q	NN	I-NP	O
's	's	POS	B-NP	O
inf	inf	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
From	From	NNP	I-NP	O
Rehab	Rehab	NNP	I-NP	O
:	:	:	O	O
10/22	10/22	CD	B-NP	O
gpc	gpc	NN	I-NP	O
in	in	IN	B-PP	O
chains	chain	NNS	B-NP	O
-LRB-	-LRB-	NN	I-NP	B-protein
?	?	.	O	O

2/4	2/4	CD	B-NP	O
bottles	bottle	NNS	I-NP	O
-RRB-	-RRB-	NNP	B-NP	O
Echo	Echo	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
TTE	TTE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
1/8	1/8	CD	I-NP	O
EF	EF	NN	I-NP	O
60-65	60-65	CD	B-NP	O
%	%	NN	I-NP	O
mild	mild	JJ	I-NP	O
LVH	LVH	NN	I-NP	O
with	with	IN	B-PP	O
restrictive	restrictive	JJ	B-NP	O
filling	filling	NN	I-NP	O
defect	defect	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
LAE/RAE	LAE/RAE	NN	I-NP	O
,	,	,	O	O
AoV	AoV	NN	B-NP	O
peak	peak	NN	I-NP	O
grad	grad	NN	I-NP	O
52mmHg	52mmHg	NN	I-NP	O
,	,	,	O	O
mean	mean	JJ	B-NP	O
2mmHg	2mmHg	NN	I-NP	O
,	,	,	O	O
peak	peak	JJ	B-NP	O
AoV	AoV	NN	I-NP	O
velocity	velocity	NN	I-NP	O
3.6	3.6	CD	B-NP	O
m/s	m/	NNS	I-NP	O
-LRB-	-LRB-	CC	O	O
elevated	elevated	JJ	B-NP	O
but	but	CC	I-NP	O
stable	stable	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	B-protein
trace	trace	NN	I-NP	I-protein
MR	MR	NNP	I-NP	I-protein
,	,	,	O	O
Trace	Trace	NNP	B-NP	O
TR	TR	NNP	I-NP	O
,	,	,	O	O
PAP	PAP	NN	B-NP	B-protein
31	31	CD	I-NP	I-protein
+	+	SYM	I-NP	O
RAP	RAP	NN	I-NP	B-protein
,	,	,	O	O
no	no	DT	B-NP	O
veg	veg	NN	I-NP	O
.	.	.	O	O

U/A	U/A	NN	B-NP	O
:	:	:	O	O
3	3	CD	B-NP	O
+	+	SYM	I-NP	O
LE	LE	NN	I-NP	O
,	,	,	O	O
7wbc	7wbc	NN	B-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
bact	bact	NN	I-NP	O
UCx	UCx	NN	I-NP	O
:	:	:	O	O
10	10	CD	B-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
colonies	colony	NNS	I-NP	O
probable	probable	JJ	B-NP	O
pseudomonas	pseudomona	NNS	I-NP	O
9/16	9/16	CD	B-NP	O
BCx	BCx	NN	I-NP	O
:	:	:	O	O
Gemella	Gemella	NN	B-NP	O
morbillorum	morbillorum	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
pansensitive	pansensitive	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
PCN	PCN	NN	B-NP	B-protein
MIC	MIC	NN	I-NP	I-protein
0.125	0.125	CD	I-NP	I-protein
-LRB-	-LRB-	HYPH	I-NP	O
intermediate	intermediate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Wound	Wound	NN	I-NP	O
Cx	Cx	NN	I-NP	O
of	of	IN	B-PP	O
suprapubic	suprapubic	JJ	B-NP	O
cath	cath	NN	I-NP	O
insertion	insertion	NN	I-NP	O
site	site	NN	I-NP	O
:	:	:	O	O
rare	rare	JJ	B-NP	O
MRSA	MRSA	NN	I-NP	O
,	,	,	O	O
few	few	JJ	B-NP	O
CNS	CNS	NNS	I-NP	B-protein
,	,	,	O	O
rare	rare	JJ	B-NP	O
enterococci	enterococci	NNS	I-NP	O
TEE	TEE	NN	I-NP	O
:	:	:	O	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
ring	ring	NN	B-NP	O
abscess	abscess	NN	I-NP	O
or	or	CC	O	O
valvular	valvular	JJ	B-NP	O
vegetation	vegetation	NN	I-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	:	O	O
A/P	A/P	NN	B-NP	O
:	:	:	O	O
8	8	CD	B-NP	O
Y/O	Y/O	NN	I-NP	O
M	M	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
mult	mult	NN	I-NP	O
med	med	JJ	I-NP	O
problems	problem	NNS	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	B-protein
recent	recent	JJ	I-NP	I-protein
AVR	AVR	NN	I-NP	I-protein
,	,	,	O	O
transferred	transfer	VBN	B-VP	O
from	from	IN	B-PP	O
rehab	rehab	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
fever	fever	NN	I-NP	O
,	,	,	O	O
+	+	SYM	B-NP	O
U/A	U/A	NN	I-NP	O
,	,	,	O	O
+	+	CC	O	O
blood	blood	NN	B-NP	O
cx	cx	NN	I-NP	O
's	's	POS	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
concern	concern	NN	B-NP	O
for	for	IN	B-PP	O
endocarditis	endocarditis	NN	B-NP	B-protein
given	give	VBN	B-VP	I-protein
recent	recent	JJ	B-NP	I-protein
AVR	AVR	NN	I-NP	I-protein
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
ceftaz	ceftaz	NN	B-NP	O
and	and	CC	I-NP	O
vanco	vanco	NN	I-NP	O
empirically	empirically	RB	B-ADVP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
and	and	CC	I-NP	O
gentamycin	gentamycin	NN	I-NP	O
once	once	RB	O	O
Gemella	Gemella	NN	B-NP	O
morbillorum	morbillorum	NN	I-NP	O
was	be	VBD	B-VP	O
identified	identify	VBN	I-VP	O
on	on	IN	B-PP	O
in-house	in-house	JJ	B-NP	B-cell_line
blood	blood	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
.	.	.	O	O

Patient	Patient	NN	B-NP	O
remained	remain	VBD	B-VP	O
afebrile	afebrile	JJ	B-NP	O
in-house	in-house	NN	I-NP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
exhibit	exhibit	VB	I-VP	O
any	any	DT	B-NP	O
significant	significant	JJ	I-NP	O
leukocytosis	leukocytosis	NN	I-NP	O
,	,	,	O	O
or	or	CC	O	O
stigmata	stigma	NNS	B-NP	O
of	of	IN	B-PP	O
endocardititis	endocardititis	NN	B-NP	O
.	.	.	O	O

Surveillance	Surveillance	NN	B-NP	O
cultures	culture	NNS	I-NP	O
drawn	draw	VBN	B-VP	O
after	after	IN	B-PP	O
starting	start	VBG	B-VP	O
antibiotics	antibiotic	NNS	B-NP	O
have	have	VBP	B-VP	O
remained	remain	VBN	I-VP	O
negative	negative	JJ	B-ADJP	O
to	to	TO	B-PP	O
date	date	NN	B-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
CP/CT/CD	CP/CT/CD	NN	I-NP	B-protein
.	.	.	O	O

Hx	Hx	NN	B-NP	O
of	of	IN	B-PP	O
CAD	CAD	NN	B-NP	B-protein
s/p	s/p	NN	I-NP	I-protein
CABG	CABG	NN	I-NP	I-protein
continue	continue	VBP	B-VP	O
w	w	NN	B-NP	O
/	/	SYM	B-NP	O
aspirin	aspirin	NN	I-NP	O
325mg	325mg	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
:	:	:	O	O
pt	pt	JJ	B-NP	O
w	w	NN	I-NP	O
hx	hx	NN	I-NP	O
of	of	IN	B-PP	O
AF	AF	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
SVR	SVR	NN	I-NP	B-protein
.	.	.	O	O

Patient	Patient	NN	B-NP	O
placed	place	VBN	B-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
for	for	IN	B-PP	O
observation	observation	NN	B-NP	O
.	.	.	O	O

Is	Be	VBZ	O	O
bradycardic	bradycardic	JJ	B-ADJP	O
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
,	,	,	O	O
asymptomatic	asymptomatic	JJ	B-ADJP	O
has	have	VBZ	B-VP	O
refused	refuse	VBN	I-VP	O
PPM	PPM	NN	B-NP	B-protein
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
per	per	IN	B-PP	O
report	report	NN	B-NP	O
.	.	.	O	O

Some	Some	DT	B-NP	O
runs	run	NNS	I-NP	O
NSVT	NSVT	NN	I-NP	O
up	up	RB	B-NP	O
to	to	TO	I-NP	O
14	14	CD	I-NP	O
beats	beat	NNS	I-NP	O
,	,	,	O	O
checking	check	VBG	B-VP	O
BID	BID	NN	B-NP	O
lytes	lyte	NNS	I-NP	O
keep	keep	VBP	B-VP	O
Mg	Mg	NN	B-NP	O
>	>	JJR	B-NP	O
2	2	CD	I-NP	O
and	and	CC	O	O
K.	K.	NNP	B-NP	O
4	4	CD	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
nodal	nodal	JJ	I-NP	O
agents	agent	NNS	I-NP	O
given	give	VBN	B-VP	O
bradycardia	bradycardia	NN	B-NP	O
.	.	.	O	O

Pump	Pump	NNP	B-NP	O
:	:	:	O	O
hx	hx	NN	B-NP	O
CHF	CHF	NN	I-NP	O
documented	document	VBD	B-VP	O
,	,	,	O	O
last	last	JJ	B-NP	O
EF	EF	NN	I-NP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

pt	pt	NN	B-NP	O
appears	appear	VBZ	B-VP	O
fluid	fluid	NN	B-NP	O
up	up	RP	B-PRT	O
,	,	,	O	O
responded	respond	VBD	B-VP	O
well	well	RB	B-ADVP	O
to	to	TO	B-PP	O
60	60	CD	B-NP	O
IV	IV	CD	I-NP	O
lasix	lasix	CD	I-NP	O
x1	x1	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
then	then	RB	B-ADVP	O
appeared	appear	VBD	B-VP	O
euvolemic	euvolemic	JJ	B-ADJP	O
and	and	CC	O	O
lasix	lasix	NN	B-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
,	,	,	O	O
for	for	IN	B-PP	O
sev	sev	NN	B-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
became	become	VBD	B-VP	O
hypervolemic	hypervolemic	JJ	B-ADJP	O
,	,	,	O	O
lasix	lasix	NN	B-NP	O
60mg	60mg	NN	I-NP	O
IV	IV	CD	I-NP	O
repeated	repeat	VBN	B-VP	O
and	and	CC	O	O
patient	patient	NN	B-NP	O
restarted	restart	VBD	B-VP	O
on	on	IN	B-PP	O
home	home	NN	B-NP	O
lasix	lasix	NN	I-NP	O
dose	dose	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
80mg	80mg	CD	I-NP	O
QAM	QAM	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
's	's	POS	B-NP	O
discharge	discharge	NN	I-NP	O
weight	weight	NN	I-NP	O
is	be	VBZ	B-VP	O
96.7	96.7	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
dry	dry	JJ	I-NP	O
weight	weight	NN	I-NP	O
is	be	VBZ	B-VP	O
approximately	approximately	RB	B-ADVP	O
93KG	93KG	NN	B-NP	O
.	.	.	O	O

Discharge	Discharge	NN	B-NP	O
weight	weight	NN	I-NP	O
is	be	VBZ	B-VP	O
96.7	96.7	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
in/out	in/out	JJ	I-NP	O
goal	goal	NN	I-NP	O
is	be	VBZ	B-VP	O
500cc	500cc	CD	B-NP	O
neg	neg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

-	-	HYPH	B-NP	O
TTE	TTE	NN	I-NP	O
neg	neg	NN	I-NP	O
for	for	IN	B-PP	O
veg	veg	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
given	give	VBN	B-VP	O
high	high	JJ	B-NP	O
risk	risk	NN	I-NP	O
,	,	,	O	O
TEE	TEE	NN	B-NP	O
obtained	obtain	VBN	B-VP	O
on	on	IN	B-PP	O
7/4	7/4	CD	B-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
endocarditis	endocarditis	NN	I-NP	O
.	.	.	O	O

Was	Wa	NNS	B-NP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
ring	ring	NN	B-NP	O
abscess	abscess	NN	I-NP	O
or	or	CC	O	O
valvular	valvular	JJ	B-NP	O
vegetationn	vegetationn	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
will	will	MD	B-VP	O
still	still	RB	I-VP	O
require	require	VB	I-VP	O
treatement	treatement	NN	B-NP	O
for	for	IN	B-PP	O
endocarditis	endocarditis	NN	B-NP	O
as	as	IN	B-PP	O
can	can	MD	B-VP	O
not	not	RB	I-VP	O
be	be	VB	I-VP	O
entirely	entirely	RB	I-VP	O
ruled	rule	VBN	I-VP	O
out	out	RP	B-PRT	O
.	.	.	O	O

Held	Held	JJ	B-NP	O
losartan	losartan	NN	I-NP	O
due	due	JJ	B-PP	O
to	to	TO	B-PP	O
acute	acute	JJ	B-NP	O
worsening	worsening	NN	I-NP	O
of	of	IN	B-PP	O
renal	renal	JJ	B-NP	O
function	function	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
initiation	initiation	NN	B-NP	O
of	of	IN	B-PP	O
gentamycin	gentamycin	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
can	can	MD	B-VP	O
resume	resume	VB	I-VP	O
use	use	VB	I-VP	O
once	once	RB	B-ADVP	O
gent	gent	JJ	B-NP	O
is	be	VBZ	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
Cr	Cr	NN	B-NP	O
slightly	slightly	RB	B-ADJP	O
elevated	elevated	JJ	I-ADJP	O
above	above	IN	B-PP	O
baseline	baseline	NN	B-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
1.1-1	1.1-1	CD	I-NP	O
.3	.3	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
on	on	IN	B-PP	O
admit	admit	NN	B-NP	O
,	,	,	O	O
likely	likely	RB	B-NP	O
2/2	2/2	CD	I-NP	O
CHF	CHF	NN	I-NP	O
and	and	CC	O	O
poor	poor	JJ	B-NP	O
forward	forward	JJ	I-NP	O
flow	flow	NN	I-NP	O
has	have	VBZ	B-VP	O
declined	decline	VBN	I-VP	O
to	to	TO	B-PP	O
near	near	JJ	B-NP	O
baseline	baseline	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
1.4	1.4	CD	B-NP	O
at	at	IN	B-PP	O
time	time	NN	B-NP	O
of	of	IN	B-PP	O
d/c	d/c	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

GU	GU	NN	B-NP	O
:	:	:	O	O
Pt	Pt	NN	B-NP	O
has	have	VBZ	B-VP	O
hx	hx	NN	B-NP	O
of	of	IN	B-PP	O
BPH	BPH	NN	B-NP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
suprapubic	suprapubic	JJ	I-NP	O
cathether	cathether	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
inserted	insert	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
surgery	surgery	NN	B-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
difficulty	difficulty	NN	B-NP	O
to	to	TO	B-VP	O
pass	pass	VB	I-VP	O
foley	foley	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
BRMC	BRMC	NN	B-NP	O
pt	pt	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
clamped	clamp	VBN	I-VP	O
repeatedly	repeatedly	RB	B-ADVP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
week	week	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
PVR	PVR	NN	I-NP	B-protein
checked	check	VBN	B-VP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
without	without	IN	B-PP	O
difficulty	difficulty	NN	B-NP	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
PVR	PVR	NN	I-NP	B-protein
of	of	IN	B-PP	O
50cc	50cc	CD	B-NP	O
.	.	.	O	O

Urology	Urology	NNP	B-NP	O
consulted	consult	VBD	B-VP	O
and	and	CC	O	O
suprapubic	suprapubic	JJ	B-NP	O
catheter	catheter	NN	I-NP	O
pulled	pull	VBD	B-VP	O
without	without	IN	B-PP	O
difficulty	difficulty	NN	B-NP	O
.	.	.	O	O

Cont	Cont	JJ	B-NP	O
dry	dry	JJ	I-NP	O
sterile	sterile	JJ	I-NP	O
dressing	dressing	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
to	to	TO	B-VP	O
wound	wound	VB	I-VP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

ID-Gemella	ID-Gemella	NN	B-NP	O
morbillorum	morbillorum	NN	I-NP	O
in	in	IN	B-PP	O
blood	blood	NN	B-NP	O
,	,	,	O	O
Pseudomonas	Pseudomonas	NN	B-NP	O
in	in	IN	B-PP	O
urine	urine	NN	B-NP	O
although	although	IN	B-SBAR	O
only	only	RB	B-NP	O
10k	10k	CD	I-NP	O
colonies	colony	NNS	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
treated	treat	VBN	B-VP	O
with	with	IN	B-PP	O
5	5	CD	B-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
ceftaz	ceftaz	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
4	4	CD	B-NP	O
days	day	NNS	I-NP	O
vanc	vanc	NN	I-NP	O
.	.	.	O	O

Decision	Decision	NN	B-NP	O
was	be	VBD	B-VP	O
made	make	VBN	I-VP	O
to	to	TO	B-PP	O
d/c	d/c	NN	B-NP	O
ceftaz	ceftaz	NN	I-NP	O
given	give	VBN	B-VP	O
only	only	RB	B-NP	O
10K	10K	CD	I-NP	O
colonies	colony	NNS	I-NP	O
Pseudomonas	Pseudomonas	NN	I-NP	O
in	in	IN	B-PP	O
urine	urine	NN	B-NP	O
and	and	CC	O	O
some	some	DT	B-NP	O
coverage	coverage	NN	I-NP	O
with	with	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
and	and	CC	O	O
gent	gent	JJ	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
started	start	VBD	B-VP	O
10/8	10/8	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
d/c	d/c	NN	I-NP	O
'd	'd	SYM	O	O
vanc	vanc	NN	B-NP	O
10/24	10/24	CD	I-NP	O
Will	Will	NNP	I-NP	O
need	need	VBP	B-VP	O
6	6	CD	B-NP	O
wks	wk	NNS	I-NP	O
ctx	ctx	NN	I-NP	O
and	and	CC	O	O
at	at	IN	B-NP	O
least	least	JJS	I-NP	O
2	2	CD	I-NP	O
wks	wk	NNS	I-NP	O
gent	gent	JJ	B-ADJP	O
for	for	IN	B-PP	O
presumed	presumed	JJ	B-NP	O
endocarditis	endocarditis	NN	I-NP	O
.	.	.	O	O

PICC	PICC	NN	B-NP	B-protein
placed	place	VBD	B-VP	I-protein
10/8	10/8	CD	B-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

GI	GI	NN	B-NP	O
-	-	HYPH	I-NP	O
continue	continue	JJ	I-NP	O
protonix	protonix	NN	I-NP	O
40	40	CD	I-NP	O
Q12	Q12	NN	I-NP	O
all	all	DT	B-NP	O
stools	stool	NNS	I-NP	O
guaiac	guaiac	NN	I-NP	O
negative	negative	JJ	B-ADJP	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-NP	O
-	-	HYPH	I-NP	O
hx	hx	NN	I-NP	O
of	of	IN	B-PP	O
IDDM	IDDM	NN	B-NP	O
will	will	MD	B-VP	O
titrate	titrate	VB	I-VP	O
up	up	RP	B-PRT	O
insulin	insulin	NN	B-NP	B-protein
to	to	TO	B-PP	O
36U	36U	NN	B-NP	O
qHS	qHS	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
insluin	insluin	NN	I-NP	O
aspart	aspart	NN	I-NP	O
SS	SS	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
-	-	HYPH	O	O
cardiac	cardiac	JJ	B-NP	O
diet	diet	NN	I-NP	O
-	-	HYPH	O	O
cont	cont	NN	B-NP	O
MVI	MVI	NN	I-NP	O
-	-	HYPH	B-NP	O
BID	BID	NN	I-NP	O
lytes	lyte	NNS	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
goal	goal	NN	I-NP	O
to	to	TO	B-VP	O
keep	keep	VB	I-VP	O
K/Mg	K/Mg	NNP	B-NP	O
March	March	NNP	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

GI	GI	NN	B-NP	O
-	-	HYPH	I-NP	O
continue	continue	JJ	I-NP	O
senna	senna	NN	I-NP	O
and	and	CC	O	O
colace	colace	NN	B-NP	B-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

Pulm	Pulm	NN	B-NP	O
-	-	HYPH	I-NP	O
cont	cont	NN	I-NP	O
flovent	flovent	NN	I-NP	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
BID	BID	NN	B-NP	O
and	and	CC	I-NP	O
albuterol	albuterol	NN	I-NP	B-protein
q12h	q12h	NN	I-NP	I-protein
9	9	CD	I-NP	I-protein
.	.	.	O	O

Heme	Heme	NNP	B-NP	B-protein
:	:	:	O	O
cont	cont	VB	B-VP	O
niferex	niferex	NN	B-NP	O
BID	BID	NN	I-NP	O
for	for	IN	B-PP	O
iron	iron	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
anemia.Pt	anemia.Pt	NN	I-NP	O
also	also	RB	B-ADVP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
eosinophilia	eosinophilia	NN	I-NP	O
on	on	IN	B-PP	O
diff	diff	NN	B-NP	O
,	,	,	O	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Derm	Derm	NN	B-NP	O
:	:	:	O	O
skin	skin	NN	B-NP	O
tear	tear	NN	I-NP	O
on	on	IN	B-PP	O
right	right	JJ	B-NP	O
hand	hand	NN	I-NP	O
,	,	,	O	O
placing	place	VBG	B-VP	O
neomycin	neomycin	NN	B-NP	O
ointment	ointment	NN	I-NP	O
and	and	CC	O	O
sterile	sterile	JJ	B-NP	O
dry	dry	JJ	I-NP	O
dressing	dressing	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

Prophylaxis-cont	Prophylaxis-cont	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
5000	5000	CD	I-NP	O
TID	TID	NN	I-NP	O
-	-	HYPH	B-NP	O
cont	cont	JJ	I-NP	O
protonix	protonix	NN	I-NP	O
40Q12h	40Q12h	NN	I-NP	O
FULL	FULL	NN	I-NP	O
CODE	CODE	NN	I-NP	O
ADDITIONAL	ADDITIONAL	NN	I-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
You	You	PRP	B-NP	O
were	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
bacterial	bacterial	JJ	I-NP	O
blood	blood	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
heart	heart	NN	I-NP	O
valve	valve	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

You	You	PRP	B-NP	O
were	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
and	and	CC	O	O
improved	improve	VBN	B-VP	O
.	.	.	O	O

PLAN	PLAN	NN	B-NP	B-protein
:	:	:	O	I-protein
1	1	LS	B-LST	I-protein
.	.	.	O	O

Continue	Continue	JJ	B-NP	O
ceftriaxone	ceftriaxone	NN	I-NP	O
for	for	IN	B-PP	O
6	6	CD	B-NP	O
weeks	week	NNS	I-NP	O
to	to	TO	B-VP	O
end	end	VB	I-VP	O
11/7/07	11/7/07	CD	B-NP	O
and	and	CC	O	O
gentamycin	gentamycin	NN	B-NP	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
for	for	IN	B-PP	O
at	at	IN	B-NP	O
least	least	JJS	I-NP	O
2	2	CD	I-NP	O
weeks	week	NNS	I-NP	O
-LRB-	-LRB-	JJ	B-ADJP	O
at	at	IN	B-ADVP	O
least	least	JJS	I-ADVP	O
until	until	IN	B-SBAR	O
11/27/07	11/27/07	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
2	2	CD	B-NP	O
.	.	.	O	O

Please	Please	VB	B-INTJ	O
go	go	VB	B-VP	O
to	to	TO	B-PP	O
your	your	PRP$	B-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
appointment	appointment	NN	B-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Ervin	Ervin	NNP	I-NP	O
Micalizzi	Micalizzi	NNP	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
infectious	infectious	JJ	I-NP	O
disease	disease	NN	I-NP	O
clinic	clinic	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Miltintergulf	Miltintergulf	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Services	Service	NNPS	I-NP	O
on	on	IN	B-PP	O
7/19/07	7/19/07	CD	B-NP	O
at	at	IN	B-PP	O
8AM	8AM	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-INTJ	O
go	go	VB	B-VP	O
to	to	TO	B-PP	O
your	your	PRP$	B-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
appointment	appointment	NN	B-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Lickert	Lickert	NNP	I-NP	O
on	on	IN	B-PP	O
10/29/07	10/29/07	CD	B-NP	O
at	at	IN	B-PP	O
12	12	CD	B-NP	O
:	:	:	O	O
45	45	CD	B-NP	O
PM	PM	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Please	Please	NNP	B-NP	O
call	call	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Harvey	Harvey	NNP	I-NP	O
Ogata	Ogata	NNP	I-NP	O
office	office	NN	I-NP	O
for	for	IN	B-PP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
rehab	rehab	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
stop	stop	VB	I-VP	O
taking	take	VBG	I-VP	O
your	your	PRP$	B-NP	O
home	home	NN	I-NP	O
losartan	losartan	NN	I-NP	O
medicine	medicine	NN	I-NP	O
while	while	IN	B-SBAR	O
you	you	PRP	B-NP	O
are	be	VBP	B-VP	O
on	on	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Dowsett	Dowsett	NNP	I-NP	O
can	can	MD	B-VP	O
decide	decide	VB	I-VP	O
when	when	WRB	B-ADVP	O
to	to	TO	B-VP	O
restart	restart	VB	I-VP	O
this	this	DT	B-NP	O
medicine	medicine	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
leaving	leave	VBG	B-VP	O
rehab	rehab	NN	B-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
you	you	PRP	B-NP	O
are	be	VBP	B-VP	O
still	still	RB	B-ADVP	O
on	on	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
have	have	VBP	B-VP	O
your	your	PRP$	B-NP	O
blood	blood	NN	I-NP	O
drawn	drawn	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

Your	Your	PRP$	B-NP	O
results	result	NNS	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
sent	send	VBN	I-VP	O
to	to	TO	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Ribas	Ribas	NNP	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
you	you	PRP	B-NP	O
have	have	VBP	B-VP	O
fever	fever	NN	B-NP	O
,	,	,	O	O
sweats	sweat	VBZ	B-VP	O
chills	chill	NNS	B-NP	O
,	,	,	O	O
rash	rash	NN	B-NP	O
,	,	,	O	O
worsening	worsen	VBG	B-VP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
chest	ch	JJS	B-NP	O
pain	pain	NN	I-NP	O
please	please	NN	I-NP	O
contact	contact	VB	B-VP	O
your	your	PRP$	B-NP	O
physician	physician	NN	I-NP	O
or	or	CC	O	O
return	return	VB	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
ER	ER	NN	I-NP	B-protein
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Continue	Continue	VB	B-VP	O
all	all	DT	B-NP	O
other	other	JJ	I-NP	O
home	home	NN	I-NP	O
meds	med	NNS	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Continue	Continue	JJ	B-NP	O
low	low	JJ	I-NP	O
salt	salt	NN	I-NP	O
,	,	,	O	O
low	low	JJ	B-NP	O
fat	fat	NN	I-NP	O
,	,	,	O	O
low	low	JJ	B-NP	O
cholesterol	cholesterol	NN	I-NP	O
diet	diet	NN	I-NP	O
,	,	,	O	O
continue	continue	VBP	B-VP	O
to	to	TO	I-VP	O
restrict	restrict	VB	I-VP	O
all	all	DT	B-NP	O
fluids	fluid	NNS	I-NP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
liters	liter	NNS	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
check	check	VB	I-VP	O
basic	basic	JJ	B-NP	O
metabolic	metabolic	JJ	I-NP	O
panel	panel	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
while	while	IN	B-SBAR	O
actively	actively	RB	B-ADVP	O
diuresing	diurese	VBG	B-VP	O
on	on	IN	B-PP	O
lasix	lasix	NN	B-NP	O
.	.	.	O	O

Then	Then	RB	O	O
check	check	VB	B-VP	O
basic	basic	JJ	B-NP	O
metabilic	metabilic	JJ	I-NP	O
panel	panel	NN	I-NP	O
twice	twice	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
lytes	lyte	NNS	B-NP	O
and	and	CC	O	O
creatinine	creatinine	NN	B-NP	O
while	while	IN	B-SBAR	O
on	on	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
draw	draw	JJ	B-NP	O
CBC	CBC	NN	I-NP	O
with	with	IN	B-PP	O
differential	differential	JJ	B-NP	O
once	once	RB	I-NP	O
weekly	weekly	JJ	I-NP	O
while	while	NN	I-NP	O
on	on	IN	B-PP	O
gent	gent	JJ	B-NP	O
and	and	CC	I-NP	O
ceftriaxone	ceftriaxone	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
draw	draw	VB	I-VP	O
gent	gent	JJ	B-NP	O
trough	trough	NN	I-NP	O
once	once	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
and	and	CC	O	O
adjust	adjust	RB	B-NP	O
gent	gent	JJ	I-NP	O
dose	dose	NN	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
consultant	consultant	NN	I-NP	O
to	to	TO	B-VP	O
determine	determine	VB	I-VP	O
whether	whether	IN	B-SBAR	O
gentamicin	gentamicin	NN	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
beyond	beyond	IN	B-PP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
5	5	CD	B-NP	O
.	.	.	O	O

Consider	Consider	VB	B-VP	O
surveillance	surveillance	NN	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
1	1	CD	B-NP	O
week	week	NN	I-NP	O
after	after	IN	B-PP	O
completing	complete	VBG	B-VP	O
antibiotic	antibiotic	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
to	to	TO	B-PP	O
document	document	NN	B-NP	O
clearance	clearance	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Please	Please	NN	B-NP	O
place	place	NN	I-NP	O
neomycin	neomycin	NN	I-NP	O
ointment	ointment	NN	I-NP	O
to	to	TO	B-PP	O
right	right	JJ	B-NP	O
hand	hand	NN	I-NP	O
lesion	lesion	NN	I-NP	O
daily	daily	JJ	I-NP	O
and	and	CC	I-NP	O
cover	cover	JJ	I-NP	O
with	with	IN	B-PP	O
dry	dry	JJ	B-NP	O
sterile	sterile	JJ	I-NP	O
dressing	dressing	NN	I-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Cont	Cont	JJ	B-NP	O
dry	dry	JJ	I-NP	O
sterile	sterile	JJ	I-NP	O
dressing	dressing	NN	I-NP	O
to	to	TO	B-PP	O
suprpubic	suprpubic	JJ	B-NP	O
cath	cath	NN	I-NP	O
site	site	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
until	until	IN	B-SBAR	O
healed	heal	VBN	B-VP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Consider	Consider	VB	B-VP	O
repeat	repeat	NN	B-NP	O
urine	urine	NN	I-NP	O
cultures	culture	NNS	I-NP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
after	after	IN	B-SBAR	O
d/c	d/c	NN	B-NP	O
to	to	TO	B-VP	O
document	document	VB	I-VP	O
clearance	clearance	NN	B-NP	O
of	of	IN	B-PP	O
pseudomonas	pseudomona	NNS	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Consider	Consider	VB	B-VP	O
restarting	restart	VBG	I-VP	O
losartan	losartan	NN	B-NP	O
after	after	IN	B-SBAR	O
gentamicin	gentamicin	NN	B-NP	O
is	be	VBZ	B-VP	O
discontinued	discontinue	VBN	I-VP	O
given	give	VBN	B-PP	O
underlying	underlie	VBG	B-VP	O
renal	renal	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Please	Please	VB	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	B-cell_line
pending	pende	VBG	B-PP	I-cell_line
blood	blood	NN	B-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
-LRB-	-LRB-	VBP	B-VP	O
no	no	DT	B-NP	O
growth	growth	NN	I-NP	O
to	to	TO	B-PP	O
date	date	NN	B-NP	O
at	at	IN	B-PP	O
time	time	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O
-RRB-	-RRB-	NN	B-NP	B-protein

11	11	CD	B-NP	O
.	.	.	O	O

Please	Please	NN	B-NP	B-protein
do	do	VBP	B-VP	O
daily	daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
on	on	IN	B-PP	O
patient	patient	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
OKIHARA	OKIHARA	NNP	B-NP	O
,	,	,	O	O
WHITNEY	WHITNEY	NNP	B-NP	O
M.	M.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
CQ197	CQ197	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
8/1/07	8/1/07	CD	I-NP	O
@	@	SYM	B-NP	O
11	11	CD	I-NP	O
******	******	SYM	I-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

